227 related articles for article (PubMed ID: 7784310)
1. Pharmacology of competitive inhibitors of HMG-CoA reductase.
Corsini A; Maggi FM; Catapano AL
Pharmacol Res; 1995 Jan; 31(1):9-27. PubMed ID: 7784310
[No Abstract] [Full Text] [Related]
2. Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
Qin W; Infante J; Wang SR; Infante R
Biochim Biophys Acta; 1992 Jul; 1127(1):57-66. PubMed ID: 1627634
[TBL] [Abstract][Full Text] [Related]
3. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis.
Alberts AW
Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667
[TBL] [Abstract][Full Text] [Related]
4. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin.
Chao Y; Chen JS; Hunt VM; Kuron GW; Karkas JD; Liou R; Alberts AW
Eur J Clin Pharmacol; 1991; 40 Suppl 1():S11-4. PubMed ID: 2044637
[TBL] [Abstract][Full Text] [Related]
5. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
[TBL] [Abstract][Full Text] [Related]
6. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Masters BA; Palmoski MJ; Flint OP; Gregg RE; Wang-Iverson D; Durham SK
Toxicol Appl Pharmacol; 1995 Mar; 131(1):163-74. PubMed ID: 7878672
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin.
Del Puppo M; Rauli S; Galli Kienle M
Lipids; 1995 Nov; 30(11):1057-61. PubMed ID: 8569435
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A; Raiteri M; Soma MR; Bernini F; Fumagalli R; Paoletti R
Am J Cardiol; 1995 Jul; 76(2):21A-28A. PubMed ID: 7604791
[TBL] [Abstract][Full Text] [Related]
9. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Carmena R
Rev Esp Cardiol; 1995 Jan; 48(1):59-65. PubMed ID: 7878284
[No Abstract] [Full Text] [Related]
10. RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
Amin D; Gustafson SK; Weinacht JM; Cornell SA; Neuenschwander K; Kosmider B; Scotese AC; Regan JR; Perrone MH
Pharmacology; 1993; 46(1):13-22. PubMed ID: 8434028
[TBL] [Abstract][Full Text] [Related]
11. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors.
Sirtori CR
Pharmacol Ther; 1993 Dec; 60(3):431-59. PubMed ID: 8073070
[TBL] [Abstract][Full Text] [Related]
12. Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolaemia.
Bard JM; Luc G; Douste-Blazy P; Drouin P; Ziegler O; Jacotot B; Dachet C; De Gennes JL; Fruchart JC
Eur J Clin Pharmacol; 1989; 37(6):545-50. PubMed ID: 2693115
[TBL] [Abstract][Full Text] [Related]
13. Compactin (ML-236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase.
Endo A
J Med Chem; 1985 Apr; 28(4):401-5. PubMed ID: 3981532
[No Abstract] [Full Text] [Related]
14. Insulin-like growth factor I enhancement of steroidogenesis by bovine granulosa cells and thecal cells: dependence on de novo cholesterol synthesis.
Spicer LJ; Hamilton TD; Keefer BE
J Endocrinol; 1996 Dec; 151(3):365-73. PubMed ID: 8994382
[TBL] [Abstract][Full Text] [Related]
15. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages.
Bernini F; Didoni G; Bonfadini G; Bellosta S; Fumagalli R
Atherosclerosis; 1993 Dec; 104(1-2):19-26. PubMed ID: 8141843
[TBL] [Abstract][Full Text] [Related]
16. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
Pappu AS; Bacon SP; Illingworth DR
J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
[TBL] [Abstract][Full Text] [Related]
17. Effect of simvastatin (MK-733) on the regulation of cholesterol synthesis in Hep G2 cells.
Nagata Y; Hidaka Y; Ishida F; Kamei T
Biochem Pharmacol; 1990 Aug; 40(4):843-50. PubMed ID: 2167097
[TBL] [Abstract][Full Text] [Related]
18. Statins do more than just lower cholesterol.
Vaughan CJ; Murphy MB; Buckley BM
Lancet; 1996 Oct; 348(9034):1079-82. PubMed ID: 8874463
[No Abstract] [Full Text] [Related]
19. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
20. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
Sakai M; Kobori S; Matsumura T; Biwa T; Sato Y; Takemura T; Hakamata H; Horiuchi S; Shichiri M
Atherosclerosis; 1997 Aug; 133(1):51-9. PubMed ID: 9258407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]